AOA Statement to FDA on Low-Dose Atropine
February 5, 2026
The American Optometric Association (AOA) acknowledges the Food and Drug Administration's (FDA) responsibility to ensure the safety and effectiveness of therapies and interventions intended for pediatric use and respects the agency’s current decision regarding low-dose atropine for the treatment of pediatric progressive myopia. The AOA encourages the FDA to continue evaluating this and other interventions for children with myopia, as the availability of an FDA-approved low-dose atropine would be beneficial to doctors and their patients. We welcome the opportunity to further collaborate with the FDA to ensure all children have access to the eye health and vision care they need.
Related News
Statement From the AOA: Consumer Health Alert for Eye Drop Recall
The American Optometric Association is issuing an alert to consumers to stop using the 26 eye drops that were recalled by the FDA.